Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Autor: Holderfield M; Revolution Medicines, Redwood City, CA, USA., Lee BJ; Revolution Medicines, Redwood City, CA, USA., Jiang J; Revolution Medicines, Redwood City, CA, USA., Tomlinson A; Revolution Medicines, Redwood City, CA, USA., Seamon KJ; Revolution Medicines, Redwood City, CA, USA., Mira A; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy., Patrucco E; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy., Goodhart G; Department of Surgery, University of Cincinnati, Cincinnati, OH, USA., Dilly J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gindin Y; Revolution Medicines, Redwood City, CA, USA., Dinglasan N; Revolution Medicines, Redwood City, CA, USA., Wang Y; Revolution Medicines, Redwood City, CA, USA., Lai LP; Revolution Medicines, Redwood City, CA, USA., Cai S; Revolution Medicines, Redwood City, CA, USA., Jiang L; Revolution Medicines, Redwood City, CA, USA., Nasholm N; Revolution Medicines, Redwood City, CA, USA., Shifrin N; Revolution Medicines, Redwood City, CA, USA., Blaj C; Revolution Medicines, Redwood City, CA, USA., Shah H; Revolution Medicines, Redwood City, CA, USA., Evans JW; Revolution Medicines, Redwood City, CA, USA., Montazer N; Revolution Medicines, Redwood City, CA, USA., Lai O; Revolution Medicines, Redwood City, CA, USA., Shi J; Revolution Medicines, Redwood City, CA, USA., Ahler E; Revolution Medicines, Redwood City, CA, USA., Quintana E; Revolution Medicines, Redwood City, CA, USA., Chang S; Revolution Medicines, Redwood City, CA, USA., Salvador A; Revolution Medicines, Redwood City, CA, USA., Marquez A; Revolution Medicines, Redwood City, CA, USA., Cregg J; Revolution Medicines, Redwood City, CA, USA., Liu Y; Revolution Medicines, Redwood City, CA, USA., Milin A; Revolution Medicines, Redwood City, CA, USA., Chen A; Revolution Medicines, Redwood City, CA, USA., Ziv TB; Revolution Medicines, Redwood City, CA, USA., Parsons D; Revolution Medicines, Redwood City, CA, USA., Knox JE; Revolution Medicines, Redwood City, CA, USA., Klomp JE; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Roth J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rees M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ronan M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cuevas-Navarro A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hu F; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lito P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Santamaria D; Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Waters AM; Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA., Der CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ambrogio C; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy., Wang Z; Revolution Medicines, Redwood City, CA, USA., Gill AL; Revolution Medicines, Redwood City, CA, USA., Koltun ES; Revolution Medicines, Redwood City, CA, USA., Smith JAM; Revolution Medicines, Redwood City, CA, USA. jan@revmed.com., Wildes D; Revolution Medicines, Redwood City, CA, USA. pete@revmed.com., Singh M; Revolution Medicines, Redwood City, CA, USA. msingh@revmed.com.

Publikováno v: Nature [Nature] 2024 May; Vol. 629 (8013), pp. 919-926. Date of Electronic Publication: 2024 Apr 08.

Consensus, debate, and prospective on pancreatic cancer treatments.

Autor: Wang, Junke^1,2,3 (AUTHOR), Yang, Jie^4,5 (AUTHOR), Narang, Amol^2,3,6 (AUTHOR), He, Jin^2,3,6,7 (AUTHOR), Wolfgang, Christopher⁸ (AUTHOR), Li, Keyu^2,3,4 (AUTHOR) keyu_li@scu.edu.cn, Zheng, Lei^2,3,6,7,9 (AUTHOR) lzheng6@jhmi.edu

Publikováno v: Journal of Hematology & Oncology. 10/11/2024, Vol. 17 Issue 1, p1-59. 59p.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

Autor: Nichols RJ; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Stahlhut C; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Schulze CJ; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Hemmati G; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Wildes D; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Tzitzilonis C; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Mordec K; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Marquez A; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Romero J; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Hsieh T; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Zaman A; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., McCoach C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Wang Z; Department of Development Sciences, Revolution Medicines, Inc., Redwood City, CA, USA., Kiss G; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Koltun ES; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA., Gill AL; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA., Singh M; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA., Goldsmith MA; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA., Smith JAM; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revolutionmedicines.com., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.

Publikováno v: Nature cell biology [Nat Cell Biol] 2018 Sep; Vol. 20 (9), pp. 1064-1073. Date of Electronic Publication: 2018 Aug 13.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.